Hookipa Pharma, a Phase 2 biotech developing T cell immunotherapies for various cancers, announced terms for its IPO on Monday.
The New York, NY-based company plans to raise $100 million by offering 6.7 million shares at a price range of $14 to $16. Insiders intend to purchase $40 million worth of shares in the offering (40% of the deal). At the midpoint of the proposed range, Hookipa Pharma would command a fully diluted market value of $412 million.
Hookipa Pharma was founded in 2011 and plans to list on the Nasdaq under the symbol HOOK. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets are the joint bookrunners on the deal. It is expected to price during the week of April 15, 2019.
